藥物基因體學市場規模、佔有率、成長分析，按產品/服務、按技術、按疾病領域、按應用、按地區 - 行業預測，2024-2031

2022年藥物基因體學市場規模為61.5億美元，從2023年的66.7億美元成長到2031年的127.8億美元，複合年成長率預計為8.47%。

受基因組研究進步、個人化醫療興起以及精準醫療進步的影響，全球市場情勢正在經歷強勁成長和轉型。人們對個人化治療選擇的認知不斷提高，加上基因組測試擴大融入臨床通訊協定，正在推動市場擴張，尤其是在慢性病變得更加普遍的情況下。此外，基因組資料和電子健康記錄的融合，以及標靶治療的出現，正在顯著增加市場活力。製藥公司、研究機構和監管機構之間的合作也大大推進了藥物基因組學研究。然而，市場面臨挑戰，包括基因檢測的高成本、限制性的報銷政策以及迫切需要廣泛的研發工作。解決這些障礙並最大限度地在臨床實踐中使用藥物基因體學對於市場的持續成功至關重要。值得注意的是，美國藥物基因體學領域預計在未來幾年將保持持續的複合年成長率，顯示該創新領域未來發展的巨大潛力和投資機會。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 技術分析
• 價值鏈分析
• 供應鏈分析
• 監管環境
• 價格分析
• 專利分析
• 客戶和購買標準分析

藥物基因體學市場：依產品和服務分類

• 市場概況
• 試劑套件和試劑
  • 定序套件和試劑
  • PCR套件和試劑
  • 微陣列套件和試劑
  • 其他套件和試劑
• 服務

藥物基因體學市場：依技術分類

• 市場概況
• 定序
• PCR
• 微陣列
• 其他技術

藥物基因體學市場：依應用分類

• 市場概況
• 個人化醫療
• 臨床調查
• 藥物發現與臨床前開發

藥物基因體學市場：依疾病領域

• 市場概況
• 癌症
• 心血管疾病
• 神經系統疾病
• 其他疾病領域

藥物基因體學市場：依最終用戶分類

• 市場概況
• 學術研究所
• 製藥和生物技術公司
• 受託研究機構

藥物基因體學市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN
• Danaher Corporation
• Laboratory Corporation of America Holdings
• Eurofins Scientific
• Charles River Laboratories
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Revvity
• IQVIA, Inc.
• Mesa Labs, Inc.
• Medpace, Inc.
• MGI Tech Co., Ltd.
• PacBio
• Takara Bio Inc.
• New England Biolabs
• BGI
• Novogene Co., Ltd.
• Sophia Genetics
• Fios Genomics
• Personalis, Inc.
• NeoGenomics Laboratories
• BioAI Health Inc.
• Macrogen, Inc.

Pharmacogenomics Market size was valued at USD 6.15 billion in 2022 and is poised to grow from USD 6.67 billion in 2023 to USD 12.78 billion by 2031, growing at a CAGR of 8.47% in the forecast period (2024-2031).

The global pharmacogenomics market is witnessing robust growth and a transformative landscape, largely influenced by breakthroughs in genomic research, the rise of personalized medicine, and the advancement of precision healthcare. A surge in awareness regarding personalized treatment options, coupled with an increasing integration of genomic testing into clinical protocols, is propelling market expansion, especially as chronic diseases become more prevalent. Furthermore, the amalgamation of genomic data with electronic health records, alongside the emergence of targeted therapies, is significantly enhancing market dynamics. Collaborative efforts among pharmaceutical firms, research institutions, and regulatory agencies are also driving considerable progress in pharmacogenomic research. Nonetheless, the market faces challenges, including the high costs associated with genetic testing, restrictive reimbursement policies, and a pressing necessity for extensive R&D efforts. Addressing these barriers and maximally utilizing pharmacogenomics in clinical settings will be crucial for the ongoing success of the market. In particular, the U.S. pharmacogenomics sector is expected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming forecast year, indicating strong potential for future development and investment opportunities within this innovative field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmacogenomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmacogenomics Market Segmental Analysis

Global Pharmacogenomics Market is segmented by Product & Service, Technology, Disease Area, Application, End User and region. Based on Product & service, the market is segmented into Kits & Reagents (Sequencing Kits and Reagents, PCR Kits and Reagents, Microarray Kits and Reagents, Other Kits and Reagents), Service. Based on Technology, the market is segmented into Sequencing, PCR, Microarray, and Other Technologies. Based on Disease Area, the market is segmented into Cancer, Cardiovascular, Neurological Diseases, Other Disease Areas. Based on Application, the market is segmented into Personalized Medicine, Clinical Research, Drug discovery & Preclinical Development. Based on End User, the market is segmented into Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Pharmacogenomics Market

The rising demand for personalized medicine significantly propels the global pharmacogenomics market, as healthcare stakeholders increasingly recognize the importance of tailoring drug therapies to individual genetic profiles. By leveraging pharmacogenomic insights, clinicians can optimize medication selection and dosages, enhancing efficacy and minimizing adverse effects, thereby leading to safer treatment regimens. This shift towards precision medicine not only improves patient health outcomes but also fosters healthcare efficiency and cost-effectiveness. As more healthcare systems integrate pharmacogenomic testing into routine practices, the market is poised for substantial growth, reflecting a broader trend towards individualized healthcare solutions that cater to each patient's unique genetic makeup.

Restraints in the Pharmacogenomics Market

The global pharmacogenomics market faces significant restraint due to the high costs associated with genetic testing and genomic analysis. These advanced tests necessitate sophisticated laboratory infrastructure and specialized expertise, resulting in expensive procedures that can limit accessibility for patients, particularly in developing regions where healthcare resources are constrained. Moreover, the complex nature of interpreting and integrating genetic data into clinical workflows demands additional specialized training and resources. These financial and technical challenges create substantial barriers to the widespread adoption of pharmacogenomic services, ultimately affecting the market's growth potential and the realization of personalized medicine benefits across diverse populations.

Market Trends of the Pharmacogenomics Market

A prominent trend in the global pharmacogenomics market is the widespread integration of personalized medicine, which tailors drug therapies to align with an individual's unique genetic profile. This paradigm shift, fueled by advancements in genomic research and increased accessibility to genetic testing technologies, empowers healthcare providers to optimize treatment efficacy and mitigate adverse drug reactions. As the healthcare industry increasingly recognizes the importance of genetic insights in medication management, the implementation of pharmacogenomics in clinical settings is anticipated to accelerate, heralding a new era of targeted therapies. This evolution not only enhances patient outcomes but also signifies robust growth potential for the pharmacogenomics market in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Regulatory Landscape
• Pricing Analysis
• Patent Analysis
• Customer & Buying Criteria Analysis

Pharmacogenomics Market, By Product & Service

• Market Overview
• Kits & Reagents
  • Sequencing Kits & Reagents
  • PCR Kits & Reagents
  • Microarray Kits & Reagents
  • Other Kits & Reagents
• Services

Pharmacogenomics Market, By Technology

• Market Overview
• Sequencing
• PCR
• Microarray
• Other Technologies

Pharmacogenomics Market, By Application

• Market Overview
• Personalized Medicine
• Clinical Research
• Drug Discovery & Preclinical Development

Pharmacogenomics Market, By Disease Area

• Market Overview
• Cancer
• Cardiovascular Disease
• Neurological Disorders
• Other Disease Areas

Pharmacogenomics Market, By End User

• Market Overview
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations

Pharmacogenomics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revvity
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesa Labs, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MGI Tech Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PacBio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novogene Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sophia Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fios Genomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Personalis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioAI Health Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macrogen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments